![Thomas Blankenstein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Thomas Blankenstein
Sociétés | Poste | Début | Fin |
---|---|---|---|
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | 01/01/2018 | - |
Fondateur | 01/01/2018 | - |
Historique de carrière de Thomas Blankenstein
Anciens postes connus de Thomas Blankenstein
Sociétés | Poste | Début | Fin |
---|---|---|---|
Medigene Immunotherapies GmbH
![]() Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Fondateur | 02/01/2013 | - |
Statistiques
Internationale
Allemagne | 3 |
Opérationnelle
Founder | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Medigene Immunotherapies GmbH
![]() Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
- Bourse
- Insiders
- Thomas Blankenstein
- Expérience